Genomic and proteomic tool market seen reaching $56.95 billion by 2030

The genomic and proteomic tool market is projected to grow from $33.14 billion in 2025 to $56.95 billion by 2030, driven by precision medicine, clinical genomics and drug discovery demand. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - The genomic and proteomic tool market sits at the center of precision medicine, drug discovery and clinical genomics. - Growth in the market points to rising demand for tools that analyze DNA, RNA and proteins for diagnosis, treatment design and biomarker discovery. - The expansion also signals more spending on biotech research, sequencing and bioinformatics infrastructure.

What happened: - The Business Research Company projected the global genomic and proteomic tool market will rise from $33.14 billion in 2025 to $37 billion in 2026. - The market is forecast to reach $56.95 billion by 2030. - The report puts the market on an 11.7% CAGR from 2025 to 2026 and an 11.4% CAGR through 2030. - North America held the largest regional share in 2025. - Asia-Pacific is expected to post the fastest growth over the forecast period.

The details: - The market’s recent growth has been supported by higher genomic research funding, next-generation sequencing advances, stronger pharmaceutical R&D, expanding academic research and lower sequencing costs. - Future growth is expected to come from precision medicine, wider clinical genomics adoption, proteomics demand in drug discovery, personalized diagnostics and advances in bioinformatics tools. - Anticipated trends include high-throughput sequencing, integrated multi-omics platforms, automated sample preparation, cloud-based bioinformatics services and broader biomarker discovery. - Genomic tools are used to study DNA and RNA, including gene sequences, expression patterns, mutations and gene interactions. - Common genomic methods include DNA sequencing, polymerase chain reaction, microarrays and genome editing. - Proteomic tools analyze protein structure, function, quantity and interactions through mass spectrometry, two-dimensional gel electrophoresis and protein microarrays. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report’s 2026 version adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - The Business Research Company offered a free sample report at the market sample. - The full report is available at the company’s market report.

Between the lines: - Personalized medicine is becoming a larger commercial driver as therapies are increasingly matched to biomarkers drawn from DNA, RNA and proteins. - The report cites a February 2024 Personalized Medicine Coalition update showing the US Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - That jump suggests more clinical use of genomic and proteomic tools as treatment development becomes more individualized.

What's next: - The market’s near-term path will likely hinge on how quickly clinical genomics, multi-omics platforms and cloud bioinformatics move from adoption to scale. - Regional competition is likely to intensify as Asia-Pacific growth narrows the gap with North America. - Drug discovery, biomarker development and personalized diagnostics should remain the main demand engines through 2030.